Abstract: SA-PO0299
Risk Stratification of Contrast-Associated AKI (CA-AKI) Using the Mehran Score in Hospitalized Patients Undergoing Contrast-Enhanced CT
Session Information
- AKI: Epidemiology and Risk Factors
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 101 AKI: Epidemiology, Risk Factors, and Prevention
Authors
- Singh, Manbir, Capital Health, Trenton, New Jersey, United States
- Adhikari, Manish, Capital Health, Trenton, New Jersey, United States
- Abood, Muhanad, Capital Health, Trenton, New Jersey, United States
- Gaire, Prativa, Capital Health, Trenton, New Jersey, United States
- Saleem, Bushra Z., Capital Health, Trenton, New Jersey, United States
Background
CA-AKI is common complication leading to prolonged hospitalization and higher healthcare costs. Mehran Score is validated tool to estimate likelihood of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention PCI. It uses clinical variables like hypotension, heart failure, baseline eGFR, diabetes, anemia, age and contrast volume to predict risk. Recent studies suggest low risk of AKI after intravenous contrast however CA-AKI remains clinically relevant, pointing to need for practical risk stratification tools to identify at-risk individuals.
Methods
In retrospective observational study, clinical data for hospitalized patients undergoing contrast-enhanced CT scans using low-osmolar iodinated contrast was analyzed. Mehran Score was calculated for each patient with AKI. Main objective of study was to identify patients with CA-AKI and to stratify them by Mehran score into low, intermediate and high-risk group. Mehran score of < 5 classified as low-risk predictor of CIN, with a 7% risk. Score of 6-15 as intermediate-risk predictor with 14-26% risk. Score above 16 as high-risk predictor with a 57% risk prediction. The inclusion criteria was patient aged 20–96 years and available serum creatinine values from baseline to 72 hours after contrast administration. Patients with ESRD, transplant or those with AKI prior to contrast were excluded.
Results
Total 310 patients were included. CA-AKI was found in 7.7% that is 24 out of 310 patients. Risk stratification analysis based on Mehran score categorized 05/24 patients (21%) as low risk, 18/24 patients (75%) as intermediate risk, and 01/24 patients (4%) as high risk. Results showed most patients fall under intermediate risk and may benefit most from targeted prophylactic measures. CA-AKI was equally distributed for age >70 years and <70 years (12 cases each) suggesting that risk is not only confined to elderly patients.
Conclusion
Mehran Score may serve as a practical risk stratification tool for CA-AKI in hospitalized patients undergoing contrast-enhanced CT although additional confirmation in larger groups is warranted. Early identification of at-risk patients, mainly within the intermediate-risk group, may help guide preventive interventions and optimize clinical decision-making when ordering contrast-enhanced CT.